Breaking News Instant updates and real-time market news.

CLDX

Celldex

$4.14

-0.06 (-1.43%)

17:27
10/09/16
10/09
17:27
10/09/16
17:27

Celldex reports Phase 2 data on glembatumumab vedotin in melanoma

Celldex Therapeutics presented results from the company's Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK inhibitor-refractory metastatic melanoma. The primary endpoint of the study -- 6 or more objective responses in the first 52 patients enrolled -- was exceeded. Seven of 62 patients experienced a confirmed response, and an additional 3 patients also experienced single timepoint responses. Median duration of response in this heavily pre-treated patient population was 6.0 months. 53% of patients experienced stable disease, with a minimum duration of six weeks. A 52% disease control rate was demonstrated. 52% of patients experienced tumor shrinkage. Median progression-free survival for all patients was 4.4 months. Patients who experienced rash in Cycle 1 experienced a 20% confirmed response rate and a more prolonged PFS of 5.5 months.

  • 09

    Oct

CLDX Celldex
$4.14

-0.06 (-1.43%)

03/08/16
JEFF
03/08/16
DOWNGRADE
Target $4
JEFF
Hold
Celldex downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin last night downgraded Celldex Therapeutics to Hold from Buy and cut his price target for the shares to $4 from $31 following yesterday's Phase 3 trial failure of Rintega.
03/08/16
BMUR
03/08/16
NO CHANGE
Target $24
BMUR
Buy
Celldex valuation inexpensive ahead of catalysts, says Brean Capital
Brean Capital noted they removed Rintega from their Celldex model before the company announced they would discontinue their Phase 3 trial. The firm sees several upcoming catalysts in the second half of the year and believes shares can be valued substantially higher than the present value. Brean Capital reiterated its Buy rating and $24 price target on Celldex shares.
03/08/16
COWN
03/08/16
NO CHANGE
Target $12
COWN
Outperform
Celldex shares oversold, says Cowen
Cowen said it was extremely disappointing that the ACT lV pivotal study for Rintega would be stopped, driven by significant performance of the control arm. The firm believes Celldex shares are oversold and the remaining pipeline is undervalued. Cowen lowered its price target to $12 from $28 on Celldex shares and maintained its Outperform rating on the stock.
10/04/16
BMUR
10/04/16
INITIATION
Target $16
BMUR
Buy
Celldex assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Celldex Therapeutics with a Buy rating and $16 price target.

TODAY'S FREE FLY STORIES

SYRS

Syros Pharmaceuticals

$16.86

-0.32 (-1.86%)

08:09
06/23/17
06/23
08:09
06/23/17
08:09
Hot Stocks
Syros Pharmaceuticals presents preclinical data on SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$11.06

0.41 (3.85%)

08:09
06/23/17
06/23
08:09
06/23/17
08:09
Hot Stocks
BlackBerry says won central bank of France as new customer »

Says cyber security…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

EA

Electronic Arts

$112.62

-0.55 (-0.49%)

08:07
06/23/17
06/23
08:07
06/23/17
08:07
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.23

2.65 (2.14%)

08:05
06/23/17
06/23
08:05
06/23/17
08:05
Hot Stocks
Alexion announces positive CHMP opinion for Soliris »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALGN

Align Technology

$149.69

0.27 (0.18%)

08:04
06/23/17
06/23
08:04
06/23/17
08:04
Recommendations
Align Technology analyst commentary  »

Align Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

TRMK

Trustmark

$31.67

-0.53 (-1.65%)

08:04
06/23/17
06/23
08:04
06/23/17
08:04
Downgrade
Trustmark rating change  »

Trustmark downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVEO

AVEO Oncology

$0.73

0.0281 (4.02%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Hot Stocks
AVEO Oncology reports positive CHMP opinion for tivozanib as RCC treatment »

AVEO Oncolog announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$170.68

0.5 (0.29%)

, HUM

Humana

$237.00

0.79 (0.33%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Recommendations
Cigna, Humana, Aetna, WellCare, Anthem, Health Net, Centene, Molina Healthcare, UnitedHealth analyst commentary  »

Jefferies says healthcare…

CI

Cigna

$170.68

0.5 (0.29%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

WCG

WellCare

$183.60

6.06 (3.41%)

ANTM

Anthem

$193.36

1.29 (0.67%)

HNT

Health Net

CNC

Centene

$83.00

2.88 (3.59%)

MOH

Molina Healthcare

$71.31

1.58 (2.27%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ZAYO

Zayo Group

$31.27

-0.54 (-1.70%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Hot Stocks
Zayo Group selected by global webscale company for wavelength solution »

A global webscale company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$47.18

0.48 (1.03%)

08:02
06/23/17
06/23
08:02
06/23/17
08:02
Hot Stocks
Williams-Sonoma to open expansive dual concept store in Seattle »

Williams Sonoma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRFT

Perficient

$17.55

0.15 (0.86%)

08:01
06/23/17
06/23
08:01
06/23/17
08:01
Hot Stocks
Perficient acquires Clarity Consulting in accretive deal »

Perficient announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NSAT

Norsat

08:01
06/23/17
06/23
08:01
06/23/17
08:01
Hot Stocks
Norsat shareholders approve plan of arrangement with Hytera Communications »

Norsat announced that at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATB

Catabasis Pharmaceuticals

$1.30

-0.01 (-0.76%)

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Hot Stocks
Catabasis Pharmaceuticals to present results from MoveDMD trial at PPMD »

Catabasis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$7.80

0.29 (3.86%)

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Options
Pandora call buyer realizes 8% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BIIB

Biogen

$280.57

1.97 (0.71%)

, SSNLF

Samsung

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Hot Stocks
Biogen's IMRALDI granted positive opinion by CHMP »

The Committee for…

BIIB

Biogen

$280.57

1.97 (0.71%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

08:00
06/23/17
06/23
08:00
06/23/17
08:00
General news
N.Y. FX Outlook: The dollar looks likely to remain on a neutral footing »

N.Y. FX Outlook: The…

FIT

Fitbit

$5.09

0.1 (2.00%)

07:59
06/23/17
06/23
07:59
06/23/17
07:59
Recommendations
Fitbit analyst commentary  »

Fitbit reorganization of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

07:59
06/23/17
06/23
07:59
06/23/17
07:59
Technical Analysis
Technical View: Hain Celestial near 52-week low in pre-market, analyst actions »

The stock is down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MEI

Methode Electronics

$40.10

1.45 (3.75%)

07:54
06/23/17
06/23
07:54
06/23/17
07:54
Recommendations
Methode Electronics analyst commentary  »

Baird remains a buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

, TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Periodicals
Foxconn's Gou still sees 50% chance of landing Toshiba chip unit, DigiTimes says »

Foxconn (HNHPF) Chairman…

HNHPF

Hon Hai Precision

TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

TOSBF

Toshiba, also use TOSYY

$2.88

-0.01 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$35.36

0.48 (1.38%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Hot Stocks
AstraZeneca announces positive CHMP opinion for Faslodex »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

V

Visa

$93.95

-0.59 (-0.62%)

07:52
06/23/17
06/23
07:52
06/23/17
07:52
Recommendations
Visa analyst commentary  »

Visa a good idea for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$19.88

0.38 (1.95%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Technical Analysis
Technical View: Cara Therapeutics at new 52-week high in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

KMX

CarMax

$62.50

2.76 (4.62%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Recommendations
CarMax analyst commentary  »

CarMax weakness on sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

07:50
06/23/17
06/23
07:50
06/23/17
07:50
General news
Treasury Market Outlook: bonds are mixed while stocks are mostly lower »

Treasury Market Outlook:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.